Treatment Satisfaction and Well-Being With Continuous Glucose Monitoring in People With Type 1 Diabetes
Author Information
Author(s): Pylov Daniel MD, PhD, Polonsky William MD, PhD, Imberg Henrik PhD, Holmer Helen MD, PhD, Hellman Jarl MD, Wijkman Magnus MD, PhD, Bolinder Jan MD, PhD, Heisse Tim MD, Dahlqvist Sofia MSc, Nyström Thomas MD, PhD, Schwarz Erik MD, PhD, Hirsch Irl MD, MACP, Lind Marcus MD, PhD
Primary Institution: Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Hypothesis
What factors contribute to improved well-being and treatment satisfaction with continuous glucose monitoring (CGM) in people with type 1 diabetes managed with multiple daily insulin injections?
Conclusion
Continuous glucose monitoring improves treatment satisfaction and patient well-being primarily through increased convenience and flexibility.
Supporting Evidence
- CGM improved treatment satisfaction by 60% due to increased convenience and flexibility.
- Patients reported feeling more cheerful, calm, and active with CGM.
- Significant improvements in well-being were observed with CGM compared to SMBG.
- Patients preferred CGM over SMBG for treatment satisfaction.
- CGM was associated with reduced perceived time with high blood glucose levels.
Takeaway
Using a special device to check blood sugar levels can make people with diabetes feel better and happier because it's easier and more flexible than traditional methods.
Methodology
The study was a randomized crossover trial comparing continuous glucose monitoring (CGM) with self-monitored blood glucose (SMBG) over 16 months, measuring well-being and treatment satisfaction through validated questionnaires.
Potential Biases
Potential bias may arise from the self-reported nature of treatment satisfaction and well-being measures.
Limitations
The study included only Caucasian adults with type 1 diabetes managed with multiple daily insulin injections, which may limit the generalizability of the findings.
Participant Demographics
Mean age was 44.6 years, with 43.9% women and a mean diabetes duration of 22.1 years.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI = 50%-69%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website